打开APP

阿斯利康与强生达成协议 在日本联合推广前列腺癌药物Zytiga

  1. Zytiga
  2. 前列腺癌
  3. 强生
  4. 阿斯利康

来源:生物谷 2013-10-12 10:22

2013年10月11日讯 /生物谷BIOON/ --阿斯利康(AstraZeneca)10月11日宣布,已与强生(JNJ)旗下杨森(Janssen)达成了一项协议,在日本联合推广Zytiga(abiraterone acetate,醋酸阿比特龙),该药是一种创新的口服药物,用于前列腺癌患者的治疗。此次合作,将为阿斯利康带来新的收入流,同时将加强其在日本的存在。协议的财务条款尚未披露。

2013年10月11日讯 /生物谷BIOON/ --阿斯利康(AstraZeneca)10月11日宣布,已与强生(JNJ)旗下杨森(Janssen)达成了一项协议,在日本联合推广Zytiga(abiraterone acetate,醋酸阿比特龙),该药是一种创新的口服药物,用于前列腺癌患者的治疗。此次合作,将为阿斯利康带来新的收入流,同时将加强其在日本的存在。协议的财务条款尚未披露。

目前,在日本前列腺癌患者的主要治疗选择为药物去势(medical castration),但许多患者的前列腺癌仍可能继续恶化,因为其他组织也会产生雄激素(endrogen)。Zytiga是一种CYP17抑制剂,能够抑制调节雄激素生产的关键酶,而雄激素能够刺激前列腺癌细胞的生长。Zytiga能够降低可作用于前列腺癌细胞的雄激素水平,这是目前前列腺癌治疗的目标。

杨森于2013年7月向日本劳动卫生福利部(MHLW)提交了Zytiga的上市申请,该药分别于2011年4月和2011年9月获FDA和欧盟委员会(EU)批准,用于转移性去势前列腺癌患者的治疗。(生物谷Bioon.com)

英文原文:AstraZeneca enters co-promotion agreement with Janssen in Japan for innovative prostate cancer treatment

Friday, 11 October 2013

AstraZeneca today announced that it has entered into an agreement with Janssen Pharmaceuticals K. K. in Japan to co-promote abiraterone acetate, an innovative oral therapy for the treatment of patients with prostate cancer.

Currently the main treatment option available to patients in Japan is medical castration, however prostate cancer can still progress in many patients because androgens are produced in other tissues. Abiraterone acetate, a CYP17-inhibitor, inhibits the key enzyme which modulates the production of androgens, hormones which stimulate prostate cancer cells to grow, from all sources in the body. This helps lower the level of androgens available to the prostate cancer cells, which is the goal of treatment in prostate cancer.
 
Janssen Pharmaceuticals K.K. submitted a marketing approval application for abiraterone acetate to the Japanese Ministry of Health, Labour and Welfare in July 2013 for the treatment of prostate cancer. The product was approved in the US by the Food and Drug Administration in April 2011, and in the EU by the European Commission in September 2011 for the treatment of patients with metastatic castration-resistant prostate cancer.
 
Marc Dunoyer, Executive Vice President, Global Products and Portfolio Strategy at AstraZeneca said: “Japan is one of the fastest growing pharmaceutical markets, where AstraZeneca has a proven track record of successfully developing and marketing innovative medicines. Abiraterone acetate is a great addition to our existing portfolio of leading cancer treatments, with real potential to address an important and growing patient need. This deal is a strong strategic fit for AstraZeneca, reinforcing both our focus on oncology as a core therapy area and Japan as one of our key growth drivers.”
 
Financial terms of the agreement were not disclosed.

版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不得转载,否则将追究法律责任。取得书面授权转载时,须注明“来源:生物谷”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。

87%用户都在用生物谷APP 随时阅读、评论、分享交流 请扫描二维码下载->